A personalized mRNA cancer vaccine developed by Moderna and Merck reduced the risk of death or recurrence by 42% in a Phase 3 trial involving 1,137 patients with stage IIB–IV melanoma. The results are considered a major advance, and both companies are already engaging with regulatory authorities for approval. Full data has been accepted by the New England Journal of Medicine.
Background
Personalized mRNA cancer vaccines are an emerging class of therapies that are engineered to target a patient's specific tumor mutations. Melanoma, the deadliest form of skin cancer, has historically had limited treatment options for advanced stages despite surgical intervention.
- Source
- Ars Technica
- Published
- Oct 23, 2026 at 06:12 AM
- Score
- 9.0 / 10